UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 16, 2009
CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 001-33537 | 20-2903562 |
| (Commission File Number) | (IRS Employer Identification No.) |
| No. 2, Jing You Road | |
| Kunming National Economy & | |
| Technology Developing District | |
| People’s Republic of China 650217 | N/A |
| (Address of Principal Executive Offices) | (Zip Code) |
0086-871-728-2628
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 16, 2009, the Board of Directors of China Shenghuo Pharmaceutical Holdings, Inc. (the “Company”) elected Xiaobo Sun, Deputy Director of the Institute of Medicinal Plant Development at the Chinese Academy of Medical Sciences, as an independent director. Dr. Sun will also be nominated as a director at the Company’s next annual meeting of stockholders.
In connection with Dr. Sun’s election, on March 16, 2009, the Company entered into an Independent Director’s Agreement with Dr. Sun. Under the terms of the Independent Director’s Agreement, Dr. Sun’s annual compensation from the Company will be 60,000 Renminbi (approximately US $8,787), payable in monthly installments of 5,000 Renminbi (approximately US $732).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. |
Date: March 20, 2009 | | |
| | By: | /s/ Gui Hua Lan |
| | | Name: Gui Hua Lan |
| | | Title: Chief Executive Officer |
